SELDI蛋白芯片技術可有效篩選血清中特異性蛋白標志物，為建立卵巢癌的診斷模型提供可靠的技術平臺。
2.4 乳腺癌
CA153用于乳腺癌的檢測，其靈敏度23％，特異性69％，只能用于監測治療效果和復發情況。LI等[23]對169例血清進行檢測，其中乳腺癌103例，正常人41例，其它乳腺疾病25例，結果發現3個潛在的新腫瘤標志物，將其組成蛋白組用來診斷分析，其靈敏度93％，特異性91％，提示該方法可用于篩選乳腺癌生物標記物。
細針穿刺細胞學檢查（FNA）是一種簡便、應用較廣的腫瘤輔助診斷方法，但對浸潤性癌與非浸潤性癌的診斷不確定，也難以得到反映乳腺癌生物學特性的一些分子生物學檢查所需的組織標本，因此在Fowler等[24]的研究中，對24例由FNA獲取的吸出物采用甲醛進行初步的固定，然后在一定條件下進行變性等處理，再采用SELDI質譜儀進行檢測，結果發現利用所得的圖譜有助于良惡性乳腺疾病的鑒別診斷，同時得到一種較簡單的獲取組織蛋白的方法，但需更多的試驗進行進一步的論證。
此外，SELDI技術還被應用于前列腺癌[25]，結腸癌[26]、頭頸部腫瘤[27]、胰腺癌[28]、胃癌[29]等的研究中，均顯示該技術有助于腫瘤的早期輔助診斷。
3、前景及展望
蛋白芯片SELDI技術除應用于腫瘤早期診斷中外，在其他疾病的研究（如艾滋病、老年性癡呆）、療效檢測、發病機制探討、新藥研發和基礎理論研究等方面亦具有廣泛應用。但是由于是一項新出現的技術，也存在一些不足之處，如小分子量蛋白質的檢測仍然沒有像大分子量蛋白質檢測那么容易，質譜檢測出的蛋白質不能直接鑒定，必須通過后續的檢測方法判斷蛋白質的種類，另外，目前全世界SELDI-TOP-MS實驗室在質控血清建立及儀器標準化狀態、自動化應用等方面存在著不統一的標準[30]，因此，對于SELDI發現的生物標記物在用于臨床診斷及其干預治療之前，必須進行嚴格的多中心和三期臨床質控驗證。隨著該技術在各種疾病中的縱深研究和技術理論不斷的完善和發展，通過大規模研究蛋白質性質、蛋白質之間相互作用及腫瘤標志物的論證和研究，推動蛋白質組學、基因組學和腫瘤學的研究進程，發現和確定越來越多的組織特異的新腫瘤標記物，從而實現疾病尤其是腫瘤的早期診斷，滿足癌癥病人的需要。
【參考文獻】
[1] Powell K．Proteomics delivers on promise of cancer biomarkers[J]. Nature Med, 2003, 9(8)：980．
[2] Issaq HJ, Veenstra TD, Conrads TP, et al．The SELDI-TOF MS approach to proteomics：Protein profiling and biomarker identification[J]. Bio-chem Biophy Res Communications, 2002, 292（3）：587-592．
[3] Issaq H,Conrads T, Prieto D, et al. SELDI-TOF MS for diagnostic proteomics[J].Anal Chem,2003,75(7):148A-155A.
[4] Kas K. On the technicalities of discovering and applying protein biomarkers for cancer prevention[J]. Eur J Cancer Prevention, 2004, 13(5):437-446.
[5] Merchant M, Weinberger S. Recent advancements in surface enhanced laser desorption/ ionization time of flight mass spectrometry[J]. Electrophoresis, 2000, 21（6）:1164-1177.
[6] El-Serag H, Mason A, Key C, et al. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United State[J]. Hepatology， 2001, 33:62-65.
[7] 吳孟超, 陳漢, 沈鋒. 原發性肝癌的外科治療——附5524例報告[J]. 中華外科雜志, 2001, 39(6):417-421.
[8] Poon TC, Chan AT, Zee B, et al. Application of classification tree and neural network algorithm to the identification of serological liver marker profiles in the diagnosis of hepatocellular carcinoma[J].Oncology,2001,61(4):275-283.
[9] Poon T, Yip T, Chan A, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes[J]. Clin Chem, 2003, 49(5):752-760.
[10] Poon TC, Hui AY, Chan HL, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: A pilot study[J]. Clin Chem, 2005, 52(2):328-335.
[11] Schwegler E, CazaresL, SteelL F, et al. SELDI-TOF-MS profiling of serum for detection of the progression of chronic hepatitis to hepatocellular carcinoma[J]. Hepatology, 2005, 41(3):634-642.
[12] Paradis V, Degos F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases[J]. Hepatology, 2005, 41(1):40-47.
[13] Ward DG, Cheng Y, N’Kontchou G, et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis[J]. Br J Cancer, 2006, 94(2):287-292.
[14] Melle C, Kaufmann R, Hommann M, et al. Proteomic profiling in microdissected hepatocellular carcinoma tissue using protein chip technology[J]. Int J Oncol, 2004, 24(4):885-891.
[15] 車國衛, 周清華. 肺癌的篩查和早期診斷[J]. 中國肺癌雜志, 2003, 6(6):412-417.
[16] Wardwell N, Massion P. Novel strategies for the early detection and prevention of lung cancer[J]. Semin Oncol, 2005, 32(3):259-268.
[17] Zhukov T, Johanson R, Cantor A, et al. Discovery of distinct protein profiles specific for lung tumors and premalignant lung lesions by SELDI mass spectrometry[J]. Lung Cancer, 2003, 40(3):267-279.
[18] 楊拴盈, 肖雪媛, 張王剛, 等. 用蛋白質芯片技術篩選非小細胞肺癌患者血清中標志蛋白[J]. 中華結核和呼吸雜志, 2006, 29(1):31-34.
[19] Whitehouse C, Solomon E. Current status of t he molecular characterization of the ovarian cancer antigen CA125 and implications for it s use in clinical screening[J]. Gynecol Oncol, 2003, 88(1pt2):152-157.
[20] Petricion EF,Ardkani AM, Hitt BA, et al． Use of proteomic patterns in serum to identify ovarian cancer[J].Lancet, 2002, 359(9306)：572-577．
[21] Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakow KB, et al. Ovarian cancer marker of 11.7kDa detected by proteomics is a serum amyloidA1[J]. Proteomics, 2005, 24:56-62.
[22] 王琪, 李力, 黎丹戎, 等. 應用飛行時間質譜技術結合蛋白芯片篩選卵巢惡性腫瘤患者的血清標志物[J].中華婦產科雜志, 2006, 41(8):544-548.
[23] Li J, Zhang Z, Rosenzwwig J, et al． Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer[J].Clin Chem,2002,48(8):1296-1304．
[24] Fowler LJ, Lovell MO, Izbicka E. Fine-needle aspiration in PreservCyt: a novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF[J]. Mod Pathol, 2004, 17(8):1012-1020.
[25] Gretzer MB, Chan DW, Van Rootselaar CL, et al. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF[J]. Prostate, 2004, 60(4):325-331.
[26] Albrethsen J, Bogebo R, Gammeltoft S, et al. Upregulated expression of human neutrophil peptides 1, 2 and 3(HNP 1-3) in colon cancer serum and tumours: a biomarker study[J]. BMC Cancer, 2005, 5:8.
[27] Wadsworth J, Kenneth D, Brendan C, et al. Identification of patients with head and neck cancer using serum protein profiles[J]. Arch Otolarygol Head Neck Surg, 2004, 130(1):98-104.
[28] Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein Ⅰ as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology[J]. Cancer Res, 2002, 62(6):1868-1875.
[29] Ebert M, Meuer J, Wiemer JC, et al. Identification of gastric cancer patients by serum protein profiling[J]. Proteome Res, 2004, 3(6):1261-1266.
[30] Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems[J]. J Natl Cancer Inst, 2004, 96(5):353-356.